Byungsuk Kim
Seoul National University · 医学
研究室紹介
Professor Byungsuk Kim's research lab specializes in developing advanced nanomaterials and immunomodulatory strategies for treating inflammatory and degenerative diseases, particularly rheumatoid arthritis, myocardial infarction, and cancer. The lab focuses on engineering multifunctional nanoparticles—such as MFC-MSNs and exosome-mimetic nanovesicles—that simultaneously scavenge reactive oxygen species (ROS), alleviate hypoxia, and reprogram immune cells (e.g., macrophages) toward anti-inflammatory phenotypes. A central theme is the modulation of the tumor and tissue microenvironments to enhance endogenous repair and immune surveillance. The lab also explores biomaterial scaffolds and stem cell therapies to improve tissue regeneration in cardiovascular and musculoskeletal disorders.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Poor O<sub>2</sub> supply to the infiltrated immune cells in the joint synovium of rheumatoid arthritis (RA) up-regulates hypoxia-inducible factor (HIF-1α) expression and induces reactive oxygen species (ROS) generation, both of which exacerbate synovial inflammation. Synovial inflammation in RA can be resolved by eliminating pro-inflammatory M1 macrophages and inducing anti-inflammatory M2 macrophages. Because hypoxia and ROS in the RA synovium play a crucial role in the induction of M1 macroph
A new homing guidance law is proposed to impact a target with a desired attitude angle. It is a variation of the conventional proportional navigation guidance (PNG) law which includes a supplementary time-varying bias. The proposed guidance law does not require a time-to-go estimation and has a simpler form. Analytic conditions for fulfilling the guidance goal are also provided. Simulation results demonstrate that the proposed guidance law has wider launch envelopes than the previous one and sho
Cancer immunotherapy modulates immune cells to induce antitumor immune responses. Tumors employ immune checkpoints to evade immune cell attacks. Immune checkpoint inhibitors such as anti-PD-L1 antibody (aPD-L1), which is being used clinically for cancer treatments, can block immune checkpoints so that the immune system can attack tumors. However, immune checkpoint inhibitor therapy may be hampered by polarization of macrophages within the tumor microenvironment (TME) into M2 tumor-associated mac
The engineering of functional smooth muscle (SM) tissue is critical if one hopes to successfully replace the large number of tissues containing an SM component with engineered equivalents. This study reports on the effects of SM cell (SMC) seeding and culture conditions on the cellularity and composition of SM tissues engineered using biodegradable matrices (5 x 5 mm, 2-mm thick) of polyglycolic acid (PGA) fibers. Cells were seeded by injecting a cell suspension into polymer matrices in tissue c
Development of localized inflammatory environments by M1 macrophages in the cardiac infarction region exacerbates heart failure after myocardial infarction (MI). Therefore, the regulation of inflammation by M1 macrophages and their timely polarization toward regenerative M2 macrophages suggest an immunotherapy. Particularly, controlling cellular generation of reactive oxygen species (ROS), which cause M1 differentiation, and developing M2 macrophage phenotypes in macrophages propose a therapeuti
Mesenchymal stem cell (MSC) implantation has emerged as a potential therapy for myocardial infarction (MI). However, the poor survival of MSCs implanted to treat MI has significantly limited the therapeutic efficacy of this approach. This poor survival is primarily due to reactive oxygen species (ROS) generated in the ischemic myocardium after the restoration of blood flow. ROS primarily causes the death of implanted MSCs by inhibiting the adhesion of the MSCs to extracellular matrices at the le
Here we show that BMCs have the potential to regenerate vascular tissues and improve patency in tissue-engineered small-diameter vascular grafts. This is the first report of a small-diameter neovessel engineered with BMCs as a cell source.